Table 1. Characteristics of included studies.
| Study | Inclusion criteria | Age (y) | Cases (n/M) | Treatment | Outcome | Side-effect | Follow-up (m) | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Experiment | Control | Experiment | Control | Experiment | Control | |||||
| Albert Lai 2011 | age > 18 years | 57.4 | 59.4 | 70/39 | 110/70 | BE | RT | OS | Y | 42 |
| newly diagnosed GB | RT | TMZ | PFS | |||||||
| KPS >60 | TMZ | Toxicity&Safety | ||||||||
| MR. Gilbert 2014 | age > 18 years | - | - | 312 | 309 | BE | RT | OS | Y | 30 |
| newly diagnosed GB | RT | TMZ | PFS | |||||||
| KPS>70 | TMZ | Toxicity&Safety | ||||||||
| MGMT status | ||||||||||
| OL. Chinot 2014 | age > 18 years | 57 | 56 | 458 | 463 | BE | RT | OS | Y | 32 |
| newly diagnosed GB | RT | TMZ | PFS | |||||||
| TMZ | KPS | |||||||||
| supratentorial | GHS | |||||||||
| B. Chauffert 2014 | ages from 18 and 70 y | 60.2 | 60.9 | 60/34 | 60/37 | BE | RT | OS | Y | 24 |
| KPS>50 | RT | TMZ | PFS | |||||||
| histologically confirmed | TMZ | OS | ||||||||
| IRI | ||||||||||
| U Herrlinger 2013 | newly diagnosed GB | 56 | 56 | 116/80 | 54/34 | BE | RT | OS | 36 | |
| KPS>70 | RT | TMZ | PFS | |||||||
| age > 18 years | TMZ | QoL | ||||||||
| IRI | ||||||||||
| JA. Carlson 2015 | age > 18 years | 55.9 | 59.5 | 30/17 | 26/16 | hypo-IMRT | hypo-IMRT | OS | Y | 60 |
| newly diagnosed GB | BE | TMZ | PFS | |||||||
| KPS>60 | TMZ | |||||||||
| KF. Hofland 2014 | age > 18 years | 62 | 59 | 32/21 | 31/18 | BE | IRI | Response Rate | Y | 31 |
| newly diagnosed GB | RT | RT | OS | |||||||
| TMZ | TMZ | PFS | ||||||||
| Jiaqi Wang 2013 | newly diagnosed GB | 53.6 | 54.7 | 27/16 | 27/14 | BE | RT | RECIST | Y | 24 |
| KPS>60 | RT | TMZ | OS | |||||||
| TMZ | ||||||||||
GB: Glioblastoma; KPS: Karnofsky performance status; RT: radiotherapy; TMZ: temozolomide; BV: bevacizumab; OS: overall survival; PFS: progression-free survival; GHS: GlobalHealthStatus; GoL:quality of life; Y: yes;